Clinical Research Of Kunduan Scorpion Combined With Leflunomide On Treating Of Refractory Rheumatoid Arthrittis

ObjectiveTo observate the clinical efficacy and safety of Kunduan scorpion combined with Leflunomide on Treating of Refractory rheumatoid arthrittis.Method60cases of refractory rheumatoid arthritis patients met the inclusion criteria in a randomized way divided into treatment and control groups. Treatment group and controlled group were given Kunduan scorpion, treatment group while given oral to fluoride Leflunomide (airuohua)20mg/territory d, continuous treatment3months. Both group courses are for12weeks, respectively, after taking4-,8-and12-week follow-up, clinical assessment and records.Observing the clinical symptoms such as tenderness joint number, swelling joint number, morning stiff time, pain VAS scoring, oint function classification, and HAQ after four weeks, eight weeks, twelwe weeks Observing the lab result such as the RF, CRP, ESR after twelwe weeks treatment; used EULAR developed of DAS28scoring as condition activities and mitigation standard;monitoring blood General, and urine General, the function of liver and kidney;to record the adverse reaction occurrenc.Resule1. Before the treatment course of age, no significant differences in patients with treatment and control groups, such on number of tenderness of joints, number of swollen joints, early morning stiff time, VAS pain score, joint function grading, HAQ index, RF, ESR, CPR, DAS28(p>0.05).2. Treatment and control groups in4weeks,8weeks,12weeks after treatment, compared to the original level, the number of joint pain, swelling, morning stiff time, on pain of patients with VAS score, joint function grading, HAQ index were proved significantly (P<0.05). Comparison of the treatment and control groups:Treatment of comparison between the two groups after4weeks joint pain, joint swelling, morning stiff time, number VAS score and joint pain in patients with functional classification and HAQ index are not statistically (p>0.05). Treatment of patients with8weeks and12weeks on joint function classification and HAQ index were proved significantly (P<0.01), in terms of improved joint function in the treatment group than the control group.3. The indexes of hemorheology include ESR and CRP were obviously decreased after treatment compared with those before treatment in two guoups(P<0.05). There are no statistic signficant difference between before and after treating in RF (p>0.05). The treatment after12weeks, compared to the two groups in RF, ESR, CPR was not statistically significant (p>0.05). Two groups can reduce inflammatory indices in cluding CRP and ESR.4. Treatment and control groups are signficant difference between before and after treating in DAS28score (P<0.05). The treatment after12weeks, compared to the two groups in DAS28score was not statistically significant (p>0.05). Two groups can reduce disease activity.5. Treatment after12weeks, treatment30cases Excellent, always have efficiency100; control group26cases Excellent,3cases of effective,1invalid, total efficiency96.7percent. Two groups was not statistically differences by Chi-square test (p>0.05).This observation, treatment of adverse reaction rate of13.3per gro up; control adverse reaction rate of10. Chi square test for adverse re action rate of the two groups,χ2=0.543,(p>0.05) was not statistica lly significant. And adverse reactions of the two groups are relatively light, by symptomatic treatment can be improved.ConclusionKunduan scorpion combined with Leflunomide and Kunduan scorpion of two treatment programmes can significantly reduce the refractory rheumatoid arthritis symptoms, signs. They played the role of xiaozhong Zhitong, improved joint function. Treatment groups in terms of reduced functional classification, HAQ index significantly better than control groups.Their adverse reactions were not significantly different.